Travoprost


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Ocular hypertension; Open-angle glaucoma As 0.003% or 0.004% solution: Instill 1 drop in the conjunctival sac of the affected eye(s) once daily, preferably in the evening.
Dosage Details
Ophthalmic
Ocular hypertension, Open-angle glaucoma
Adult: As 0.003% or 0.004% solution: Instill 1 drop in the conjunctival sac of the affected eye(s) once daily, preferably in the evening.
Child: ≥3 years As 0.003% solution: Same as adult dose.
Special Precautions
Patients with risk factors of cystoid macular oedema, history of intraocular inflammation (e.g. uveitis, iritis). Aphakic, and pseudophakic patients with torn posterior lens capsule. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Iris hyperpigmentation, macular oedema, bacterial keratitis, changes in length, thickness, pigmentation or number of eyelashes.
Eye disorders: Ocular hyperaemia, cataract, conjunctivitis, decreased visual acuity, blurred vision, blepharitis, corneal staining, ocular inflammation, photophobia, crusting of eyelid margin, foreign body sensation in eyes, deepening of eyelid sulcus, eye tearing, pain in the eye, dry eye, ocular pruritus, ocular discomfort.
Patient Counseling Information
Remove contact lenses prior to ophth administration and reinsert after 15 minutes. This drug may cause transient effects on vision, if affected, do not drive or operate machinery.
Action
Description: Travoprost is a highly selective full agonist prostaglandin F2α analogue with high affinity to prostaglandin FP receptor. It reduces intraocular pressure by increasing outflow of aqueous humour through trabecular meshwork and uveoscleral pathways.
Onset: Approx 2 hours.
Pharmacokinetics:
Absorption: Absorbed through the cornea. Time to peak plasma concentration: Within 1-2 hours.
Metabolism: Metabolised in the cornea via hydrolysis by esterases to active free acid; further metabolised systematically into inactive metabolites via β-oxidation of the α-carboxylic acid chain; oxidation of 15-hydroxyl moiety; and reduction of the 13, 14 double bond.
Excretion: Via urine (<2% as free acid). Elimination half-life: 45 minutes.
Chemical Structure

Chemical Structure Image
Travoprost

Source: National Center for Biotechnology Information. PubChem Database. Travoprost, CID=5282226, https://pubchem.ncbi.nlm.nih.gov/compound/Travoprost (accessed on Jan. 23, 2020)

Storage
Store between 2-25°C.
ATC Classification
S01EE04 - travoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
References
Anon. Travoprost. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 02/01/2019.

Anon. Travoprost. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/01/2019.

Buckingham R (ed). Travoprost. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/01/2019.

Izba (Novartis Europharm Limited). European Medicines Agency [online]. Accessed 02/01/2019.

Joint Formulary Committee. Travoprost. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 28/01/2015.

McEvoy GK, Snow EK, Miller J et al (eds). Travoprost (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 28/01/2015.

Travatan and Travatan Z. U.S. FDA. https://www.fda.gov/. Accessed 28/01/2015.

Travatan Z (Alcon Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/01/2019.

Disclaimer: This information is independently developed by MIMS based on Travoprost from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in